[ad_1]
Adjusted earnings were $1.34 per share, up 129% year over year, beating earnings estimates of $1.08 per share on roughly $22.6 billion in sales from analysts surveyed by FactSet.
The growth comes despite U.S. sales of the COVID vaccine slipping from more than $2 billion in the second quarter to under $1.6 billion during the third quarter. That trend could be reversed now that federal authorities have cleared a third dose for certain vulnerable populations and a smaller dose for use in children ages 5 to 11. The U.S. Centers for Disease Control and Prevention will vote today on its use and rollout for the age-group.
The U.S. government has already bought 115 million children’s doses of the Pfizer vaccine, which is the only one to have received emergency-use authorization for the age-group.
Pfizer now expects full-year revenue of $81 billion to $82 billion and adjusted earnings of $4.13 to $4.18 per share.
Company shares were up 3% in premarket trading on the results.
This story first appeared in our sister publication, Crain’s New York Business.
[ad_2]
Source link
